DYN
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Article Summary
BUY- Dyne Therapeutics Inc. (Nasdaq: DYN) announced that the U.S.
- Food and Drug Administration accepted for review the Biologics License Application (BLA) for zeleciment rostudirsen for the treatment of individuals with Duchenne muscular dystrophy amenable to exon 51 skipping, with the FDA granting the BLA Priority Review and assigning a PDUFA target action date of January 21, 2027.
- The clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases demonstrated robust and statistically significant increase in dystrophin production with functional improvement observed across multiple clinical endpoints and favorable safety profile in the registrational expansion cohort of the DELIVER trial.
- Treatment with z-ro STUDirsen once every 4 weeks resulted in a robust and statistical significant increase.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.4% | 25% | 50.0 ptsMeets Minimum (15.4%) - Passes screener |
| Target Price Upside ? | 66.2% | 20% | 100.0 ptsMassive Upside (66.2%) - Target: $39.20 vs Current: $23.58 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -5.7% | 15% | 20.0 ptsBarely a Dip (-5.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.